Posters

EYE-LIGHT® technology for the management of Meibomian gland dysfunction (MGD)

Poster Details

First Author: A.Rodriguez SPAIN

Co Author(s):    O. Al-Shymali   M. Rosello-Martinez   J. Alió              

Abstract Details

Purpose:

To evaluate the effects of EYE-LIGHT® Treatment Protocol (OPE® TECHNOLOGY combined with LIGHT MODULATION®) in the treatment of meibomian gland dysfunction (MGD) in a prospective study. OPE® TECHNOLOGY is a polychromatic light which uses thermal pulses and LIGHT MODULATION® is a unique technology of photobiomodulation that allows endogenous heating of the eyelids. The combine use of both stimulates the contraction of the meibomian glands and facilitates the spill of them, stabilizing the lipid layer of the tear.

Setting:

VISSUM INNOVATION, Alicante, Spain.

Methods:

Patients with refractory MGD to conventional treatments were enrolled and underwent 4 OPE®- LIGHT MODULATION® treatment sessions at baseline, 15, 30, 60 days. The ocular surface disease index (OSDI) score, subjective symptom score using visual analogue scales (VAS) per each eye, height of the meniscus lacrimal, NIBUT (Non Invasive Break-Up Time), detection and automatic classification of bulbar redness and meibography (Meibo-Scan) of the upper and lower eyelids, were assessed at baseline and at 15, 30, 60 days after treatments. The frequency of administration of artificial tears was also recorded in each visit.

Results:

24 eyes of 12 patients (mean age ± SD, 59.1 ± 15.8 years) were enrolled. The OSDI score improved after the therapy from severe dry eye (36) to mild dry eye (21) at 60 days. The subjective symptoms score with the VAS scale (range from 0-100) improved from 42 to 19 after the same time. The height of the meniscus lacrimal, bulbar redness and meibography grading remained stable. The NIBUT values improved an average of 2.3 seconds at 60 days with respect to baseline and the frequency of administration of artificial tears decreased from 4.7 to 2.8 times a day.

Conclusions:

The EYE-LIGHT® Treatment Protocol using the OPE® TECHNOLOGY combined with the LIGHT MODULATION® in 4 consecutive sessions improved the symptoms (OSDI and VAS) and NIBUT, and decreased the frequency of administration of artificial tears in the patients with MGD after 60 days of treatments.

Financial Disclosure:

None